West Pharmaceutical Services, Inc.
WSTNYSEHealthcare● Active
$319.75
+$5.25(+1.67%)
Market Cap$22.6B
P/E Ratio—
52W High$330.88
52W Low$206.8
West Pharmaceutical Services, Inc. (WST) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · WST · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $0.49B | $0.49B | $0.59B | $0.59B | $0.66B |
| Depreciation & Amort. | $0.17B | $0.16B | $0.14B | $0.12B | $0.12B |
| Stock-Based Comp. | $0.02B | $0.02B | $0.02B | $0.02B | $0.04B |
| Change in Working Capital | $0.08B | $0.00B | ($0.02B) | ($0.01B) | ($0.19B) |
| Net Cash from Operations | $0.75B | $0.65B | $0.78B | $0.72B | $0.58B |
| Investing Activities | |||||
| Capital Expenditure | ($0.29B) | ($0.38B) | ($0.36B) | ($0.28B) | ($0.25B) |
| Purchases of Investments | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Sales of Investments | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Cash from Investing | ($0.29B) | ($0.38B) | ($0.37B) | ($0.29B) | ($0.25B) |
| Financing Activities | |||||
| Common Stock Repurchased | ($0.13B) | ($0.57B) | ($0.45B) | ($0.22B) | ($0.15B) |
| Dividends Paid | ($0.06B) | ($0.06B) | ($0.06B) | ($0.05B) | ($0.05B) |
| Debt Issued / Repaid | ($0.00B) | ($0.03B) | ($0.00B) | ($0.04B) | ($0.00B) |
| Net Cash from Financing | ($0.19B) | ($0.62B) | ($0.46B) | ($0.29B) | ($0.17B) |
| Free Cash Flow | |||||
| Free Cash Flow | $0.47B | $0.28B | $0.41B | $0.44B | $0.33B |
| FCF Margin %(computed) | 15.26% | 9.56% | 14.05% | 15.23% | 11.68% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B
Explore more West Pharmaceutical Services, Inc. data
About West Pharmaceutical Services, Inc. (WST) Cash Flow Statement
West Pharmaceutical Services, Inc. generated operating cash flow of $0.75B and free cash flow of $0.47B for 2025 — a FCF margin of 15.26%. Capital expenditure was ($0.29B).
Frequently asked questions
WST · 4 questionsWest Pharmaceutical Services, Inc. generated free cash flow of $0.47B for 2025, up 69.6% year-over-year.
WST free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10